← Leaderboards
David R Clemmons
Vascular Pharmaceuticals
$2,553,608
Attributed
$2,553,608
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $747.7K · FY2009–16$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,553,608 · 3
By mechanism
R42$2,380,695 · 2
R41$172,913 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Amino Acids”
- Gaetano T Montelione · Rutgers The St Univ Of Nj New Brunswick$51,685,372
- Andrzej Joachimiak Joachimiak · University Of Chicago$50,824,569
- Paul S. Aisen · Cognition Therapeutics, Inc.$49,774,251
- Alex Bateman · European Molecular Biology Laboratory$45,287,965
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- John P Moore · Weill Medical College Of Cornell Univ$37,501,350
Research focus
Amino AcidsAffinityAntibodiesInsulin-Like Growth Factor IHyperglycemiaEpitopesMonoclonal AntibodiesSignal TransductionBiochemicalInhibiting AntibodyPreventPharmaceutical PreparationsComplicationResponseComputer SimulationProteinsPeptidesPublic Health Medicine (Field)Injection Of Therapeutic AgentBinding (Molecular Function)Chinese Hamster Ovary CellHumanized AntibodyImmunogenicCell Line
Grant awards (5)
Development of a novel method for inhibiting diabetic retinopathy$579,202
R42 · FY2016 · EY · contact PI
Development of a novel method for inhibiting diabetic retinopathy$583,208
R42 · FY2015 · EY · contact PI
Development of a novel method for inhibiting diabetic retinopathy$172,913
R41 · FY2012 · EY · contact PI
Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes$470,596
R42 · FY2010 · HL · contact PI
Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes$747,689
R42 · FY2009 · HL · contact PI